Keyword: Merck

Elliot Ehrich, M.D., who capped an 18-year career at Alkermes in January, has joined Expansion Therapeutics as its chief medical officer.

Combining a RIP1 inhibitor with Merck's hit checkpoint inhibitor Keytruda holds promise in treating pancreatic cancer, GSK says.

Aduro has reported first data for STING agonist ADU-S100, hoping to rebuild confidence in the mechanism after lackluster data from Merck at ESMO.

Eli Lilly is dropping a BACE inhibitor that was being tested in combination in Alzheimer's disease.

SITC kicked off with a stack of new data on immuno-oncology drugs, including a first look at Merck’s early-stage drugs targeting LAG-3 and TIGIT.

Celgene has poached a new R&D executive as it hopes to shake off past problems with a shake-up of its research unit.

Bayer and Loxo Oncology have published the latest updated data for larotrectinib at ESMO.

Amid high expectations, the first clinical data with Merck & Co’s STING agonist at ESMO has proved a disappointment—at least as a monotherapy.

Merck beefs up digital work with consumer executive; F-star names ex-Immunocore CEO as leader; and Ziopharm’s R&D head joins Spectrum as CMO.

CuraSen Therapeutics has pulled off a $54.5 million series A funding round as it gains big-name backing to help tackle neurodegenerative disorders.